Premium
P2‐086: Evaluation of CSF Aβ40 with a new immunoassay Innotest β amyloid 1‐40 prototype kit in Alzheimer's disease and apparented syndromes
Author(s) -
Ferrari Patricia
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.976
Subject(s) - immunoassay , monoclonal antibody , biomarker , antibody , amyloid (mycology) , medicine , pathology , immunology , chemistry , biochemistry
both serum and plasma samples to determine the relationship between serum and plasma levels of each. We selected 11 protein biomarkers that (1) have high (greater than 0.75) expression correlation between serum and plasma; (2) are significantly associated with AD status in the TARC cohort. We built a diagnostic algorithm with these 11 biomarkers using the TARC cohort as a training set, and validated the algorithm independently on the ADNI cohort as a testing set.Results:When the diagnostic algorithm developed on the TARC dataset and applied to the ADNI dataset, the prediction accuracy, sensitivity and specificity were 0.65, 0.61, and 0.74 respectively in distinguishing the AD patients from cognitive healthy controls. When combined with the clinical variables (age, gender, education, and APOE status), the prediction accuracy, sensitivity and specificity were 0.81, 0.84, and 0.76 respectively. Conclusions: These results validated the usefulness of the biomarkers algorithm in diagnosis of AD with both serum and plasma samples. The study also demonstrated by carefully selecting appropriate protein biomarkers, it is possible to develop a diagnostic algorithm that can be applied to both serum and plasma measurements.